Improved Synthesis, Anticancer Activity and Electrochemical Characterization of Unusual Zwitterionic Palladium Compounds with a Ten‐Term Coordinative Ring.

[1]  Johanna Smeyers-Verbeke,et al.  Chapter 28 - Introduction to Part B , 1998 .

[2]  M J Clarke,et al.  Non-platinum chemotherapeutic metallopharmaceuticals. , 1999, Chemical reviews.

[3]  S. Roland,et al.  Chiral diaminocarbene palladium(II) complexes: synthesis, reduction to Pd(0) and activity in the Mizoroki–Heck reaction as recyclable catalysts , 2003 .

[4]  N. Veldman,et al.  Stereospecific Reaction of Molecular Halogens with Palladacyclopentadienes Containing Bidentate Nitrogen Ligands To Give 1,4-Dihalo-1,3-dienes via Palladium(IV) Intermediates. , 2003 .

[5]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[6]  P. Dyson,et al.  Metal-based antitumour drugs in the post genomic era. , 2006, Dalton transactions.

[7]  M. Jakupec,et al.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). , 2006, Journal of inorganic biochemistry.

[8]  Dulal Panda,et al.  Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes. , 2007, Journal of the American Chemical Society.

[9]  A. Casini,et al.  Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. , 2008, Journal of medicinal chemistry.

[10]  M. Jakupec,et al.  Antitumour metal compounds: more than theme and variations. , 2008, Dalton transactions.

[11]  A. Gennaro,et al.  Electronic properties of chelating dicarbene palladium complexes: A combined electrochemical, NMR and XPS investigation , 2010 .

[12]  Shonagh Walker,et al.  The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.

[13]  T. Rüffer,et al.  (Metallocenylphosphane)palladium Dichlorides – Synthesis, Electrochemistry and Their Application in C–C Coupling Reactions , 2011 .

[14]  A. Casini,et al.  Molecular mechanisms and proposed targets for selected anticancer gold compounds. , 2011, Current topics in medicinal chemistry.

[15]  G. Deacon,et al.  Palladium Complexes with the SC6F4H‐4 Ligand – Synthesis, Spectroscopy, and Structures , 2013 .

[16]  A. Kapdi,et al.  Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes. , 2014, Chemical Society reviews.

[17]  A. Paci,et al.  Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics. , 2014, European journal of cancer.

[18]  S. Altuwaijri,et al.  Synthesis, spectroscopic characterization, X-ray structure and electrochemistry of new bis(1,2-diaminocyclohexane)gold(III) chloride compounds and their anticancer activities against PC3 and SGC7901 cancer cell lines , 2014 .

[19]  V. Bertolasi,et al.  The addition of bromine and iodine to palladacyclopentadienyl complexes bearing bidentate heteroditopic P-N spectator ligands derived from differently substituted quinolinic frames. The unexpected evolution of the reaction. , 2015, Dalton transactions.

[20]  D. Erdogan,et al.  Spectroelectrochemical Investigation of Nuclease Active Pt(II) Complexes Containing Pyrrole Oxime , 2015 .

[21]  V. Bertolasi,et al.  Synthesis and characterization of palladacyclopentadiene complexes with N-heterocyclic carbene ligands , 2015 .

[22]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[23]  V. Bertolasi,et al.  The addition of halogens and interhalogens on palladacyclopentadienyl complexes bearing quinolyl-thioether as spectator ligands. A kinetic and computational study , 2016 .

[24]  Víctor Cerdà,et al.  Optimization using the gradient and simplex methods. , 2016, Talanta.

[25]  V. Bertolasi,et al.  The unexpected case of reactions of halogens and interhalogens with halide substituted Pd(ii) σ-butadienyl complexes. , 2016, Dalton transactions.

[26]  C. Chung,et al.  Cyclometalated Palladium(II) N-Heterocyclic Carbene Complexes: Anticancer Agents for Potent In Vitro Cytotoxicity and In Vivo Tumor Growth Suppression. , 2016, Angewandte Chemie.

[27]  V. Bertolasi,et al.  Addition of halogens and interhalogens on palladacyclopentadienyl complexes stabilized by pyridyl−thioether N−S spectator ligands , 2016 .

[28]  C. Amatore,et al.  Molecular electrochemistry: A central method to understand the metabolic activation of therapeutic agents. The example of metallocifen anti-cancer drug candidates , 2017 .

[29]  P. Ottevanger.  Ovarian cancer stem cells more questions than answers. , 2017, Seminars in cancer biology.

[30]  N. Demitri,et al.  Reactivity of N-heterocyclic carbene-pyridine palladacyclopentadiene complexes toward halogen addition. The unpredictable course of the reaction. , 2017, Dalton transactions.

[31]  T. Connor,et al.  A review of high performance liquid chromatographic-mass spectrometric urinary methods for anticancer drug exposure of health care workers. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[32]  N. Tinari,et al.  FPSE-HPLC-DAD method for the quantification of anticancer drugs in human whole blood, plasma, and urine. , 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[33]  B. Casetta,et al.  Practical fluorimetric assay for the detection of anticancer drug SN‐38 in human plasma , 2018, Journal of pharmaceutical and biomedical analysis.

[34]  U. Karst,et al.  Structure elucidation and quantification of the reduction products of anticancer Pt(iv) prodrugs by electrochemistry/mass spectrometry (EC-MS)† †Electronic supplementary information (ESI) available: Experimental part, mass voltammograms, EC-LC-MS analysis. See DOI: 10.1039/c8an00258d , 2018, The Analyst.

[35]  Giuseppe Toffoli,et al.  Voltammetric behaviour of the anticancer drug irinotecan and its metabolites in acetonitrile. Implications for electrochemical therapeutic drug monitoring , 2018, Electrochimica Acta.

[36]  W. Berger,et al.  Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. , 2018, Chemical Society reviews.

[37]  R. Gambari,et al.  Synthesis of new allyl palladium complexes bearing purine-based NHC ligands with antiproliferative and proapoptotic activities on human ovarian cancer cell lines. , 2018, Dalton transactions.

[38]  Yvonne E. Moussa,et al.  The side effects of platinum-based chemotherapy drugs: a review for chemists. , 2018, Dalton transactions.

[39]  A. R. Fernandes,et al.  Spectroscopy, electrochemistry and antiproliferative properties of Au(iii), Pt(ii) and Cu(ii) complexes bearing modified 2,2':6',2''-terpyridine ligands. , 2018, Dalton transactions.

[40]  P. Canton,et al.  Synthesis of novel allyl palladium complexes bearing purine based NHC and a water soluble phosphine and their catalytic activity in the Suzuki‐Miyaura coupling in water , 2018 .

[41]  V. Ganesan,et al.  Electrochemical sensor and biosensor platforms based on advanced nanomaterials for biological and biomedical applications. , 2018, Biosensors & bioelectronics.

[42]  N. Demitri,et al.  Synthesis and in-depth studies on the anticancer activity of novel palladacyclopentadienyl complexes stabilized by N-Heterocyclic carbene ligands. , 2019, European journal of medicinal chemistry.

[43]  R. Gambari,et al.  Palladium (0) olefin complexes bearing purine-based N-heterocyclic carbenes and 1,3,5-triaza-7-phosphaadamantane (PTA): Synthesis, characterization and antiproliferative activity toward human ovarian cancer cell lines , 2019, Journal of Organometallic Chemistry.

[44]  R. Gambari,et al.  Palladacyclopentadienyl complexes bearing purine‐based N‐heterocyclic carbenes: A new class of promising antiproliferative agents against human ovarian cancer , 2019, Applied Organometallic Chemistry.